See more : Black Mountain Gold USA Corp. (BMGCF) Income Statement Analysis – Financial Results
Complete financial analysis of Mindset Pharma Inc. (MSSTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mindset Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- TeraWulf Inc. (WULF) Income Statement Analysis – Financial Results
- Hangzhou Huaguang Advanced Welding Materials Co., Ltd. (688379.SS) Income Statement Analysis – Financial Results
- Nagarro SE (NA9.DE) Income Statement Analysis – Financial Results
- Klondike Silver Corp. (KLSVF) Income Statement Analysis – Financial Results
- Kimura Co.,Ltd. (7461.T) Income Statement Analysis – Financial Results
Mindset Pharma Inc. (MSSTF)
About Mindset Pharma Inc.
Mindset Pharma Inc. develops and sells psychedelic medicines to treat neurological and psychiatric disorders in Canada. It focuses on developing MSP-1014, a psychedelic drug candidate. The company is based in Toronto, Canada.
| Metric | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Revenue | 3.91M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.91M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.39M | 2.22M | 0.00 | 0.00 |
| General & Administrative | 13.09M | 6.24M | 45.62K | 13.95K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.09M | 6.24M | 45.62K | 13.95K |
| Other Expenses | -33.41K | -71.37K | 0.00 | 0.00 |
| Operating Expenses | 20.48M | 8.46M | 45.62K | 13.95K |
| Cost & Expenses | 20.48M | 8.46M | 45.62K | 13.95K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 44.53K | 22.26K | 171.86K | 161.14K |
| EBITDA | -16.53M | -5.32M | -58.15K | -13.95K |
| EBITDA Ratio | -423.29% | 0.00% | 0.00% | 0.00% |
| Operating Income | -16.58M | -5.35M | -58.15K | -13.95K |
| Operating Income Ratio | -424.43% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -33.41K | -6.31M | 25.04K | 0.00 |
| Income Before Tax | -16.61M | -11.65M | -33.10K | -13.95K |
| Income Before Tax Ratio | -425.29% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.12M | 0.00 | 0.00 |
| Net Income | -16.61M | -11.65M | -33.10K | -13.95K |
| Net Income Ratio | -425.29% | 0.00% | 0.00% | 0.00% |
| EPS | -0.18 | -0.20 | 0.00 | 0.00 |
| EPS Diluted | -0.18 | -0.20 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 90.06M | 57.66M | 66.14M | 66.14M |
| Weighted Avg Shares Out (Dil) | 90.06M | 57.66M | 66.14M | 66.14M |
HC Wainright & Co initiates coverage of Mindset Pharma with a Buy rating and C$5 price target
HC Wainwright & Co has started coverage on psychedelics firm Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) with a 'Buy' rating and a C$5 price target. The Canadian company is advancing psychedelic-based treatments using a rigorous scientific process through clinical trials.
Mindset Pharma ends its first full fiscal year with $6.6M in cash to advance novel psychedelic portfolio
Mindset Pharma Inc reported its FY 2021 financial results showing the psychedelics firm ended the year with a cash balance of $6.6 million. In a statement, the Toronto-based company told shareholders that it is “well capitalized” to execute on its...
Mindset Pharma says it has expanded benchmark data for psychedelics under COPE program with InterVivo Solutions
Mindset Pharma Inc announced that it has developed its first-generation psychedelics benchmark data under the Co-operative Psychedelics Evaluation Platform (COPE) program in collaboration with InterVivo Solutions, a preclinical contract research organization. The Toronto-based psychedelic company said that its benchmark data was...
Mindset Pharma Expands Benchmarking Data for First Generation Psychedelics Through the COPE Program with InterVivo Solutions
TORONTO, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric...
Mindset Pharma identifies additional next-generation 5-MeO-DMT-inspired lead candidates
Mindset Pharma Inc. reports that, in addition to its potential lead new chemical entity (NCE) candidate MSP-4018, it has identified two additional pipeline opportunities from its Family 4 compounds MSP-4019 and MSP-4020.
Mindset Pharma Expands Pipeline: Identifies Additional Next Generation 5-MeO-DMT-Inspired Lead Candidates
Preclinical data demonstrated efficacy and an improved safety profile of MSP-4019 and MSP-4020 in head-to-head comparisons against 5-MeO-DMT Preclinical data demonstrated efficacy and an improved safety profile of MSP-4019 and MSP-4020 in head-to-head comparisons against 5-MeO-DMT
Mindset Pharma added to NYSE-listed AdvisorShares Psychedelics ETF
Mindset Pharma Inc has been added to a leading New York Stock Exchange-listed psychedelics exchange-traded fund. The Toronto-based drug discovery firm announced its inclusion in the AdvisorShares Psychedelics ETF, which trades on the NYSE Arca under the symbol ‘PSIL.
Mindset Pharma Announces Inclusion in NYSE Listed AdvisorShares Psychedelics Exchange Traded Fund (ETF)
TORONTO, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric...
Mindset Pharma says further preclinical results for its MSP-4018 drug candidate demonstrate strong efficacy and improved safety profile
Mindset Pharma Inc has announced that preclinical proof-of-concept data comparing its clinical candidate, MSP-4018, against 5-MeO-DMT further demonstrate strong efficacy and an improved safety profile as a next-generation psychedelic medicine. Mindset, a drug discovery and development company focused on creating next-generation...
Mindset Pharma Announces Further Preclinical Results Demonstrating Strong Efficacy and Improved Safety Profile for its 5-MeO-DMT-Inspired Drug Candidate, MSP-4018
TORONTO, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric...
Source: https://incomestatements.info
Category: Stock Reports